DCPH - Near a 2-Year Low Is Deciphera Pharmaceuticals a Buy?
Shares of Deciphera Pharmaceuticals (NASDAQ: DCPH) are trading close to a 52-week low of $33.55 -- pretty far from the $57.89 they commanded last year at this time. The company, which went public with an IPO in 2017, got a big bump late in 2019 on positive phase 3 trials for its lead drug, Qinlock (ripretinib).
The company's stock has fallen significantly since then, but this might provide a good buying opportunity for investors. Deciphera stock is down more than 39% this year and more than 37% over the past 12 months.
IMAGE SOURCE: GETTY IMAGES.
For further details see:
Near a 2-Year Low, Is Deciphera Pharmaceuticals a Buy?